Hunan Jingfeng Pharmaceutical (000908) - Total Liabilities
Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) has total liabilities worth CN¥915.74 Million CNY (≈ $134.00 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 000908 net asset momentum to track the company's year-over-year net asset growth rate.
Hunan Jingfeng Pharmaceutical - Total Liabilities Trend (1995–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. See Hunan Jingfeng Pharmaceutical free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Hunan Jingfeng Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Hunan Jingfeng Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alerus Financial Corp
NASDAQ:ALRS
|
USA | $4.71 Billion |
|
MBK Public Company Limited
BK:MBK-R
|
Thailand | ฿37.46 Billion |
|
Global Top E Commerce Co Ltd
SHE:002640
|
China | CN¥2.45 Billion |
|
Shenzhen Minglida Precision Technology Co. Ltd.
SHE:301268
|
China | CN¥4.41 Billion |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
Germany | €1.86 Billion |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$15.71 Million |
|
TTET Union Corp
TW:1232
|
Taiwan | NT$3.85 Billion |
|
Mid Penn Bancorp
NASDAQ:MPB
|
USA | $5.32 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Hunan Jingfeng Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hunan Jingfeng Pharmaceutical.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 24.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Jingfeng Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Jingfeng Pharmaceutical (1995–2024)
The table below shows the annual total liabilities of Hunan Jingfeng Pharmaceutical from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥955.11 Million ≈ $139.76 Million |
-21.33% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.65 Million |
-3.16% |
| 2022-12-31 | CN¥1.25 Billion ≈ $183.45 Million |
-14.40% |
| 2021-12-31 | CN¥1.46 Billion ≈ $214.31 Million |
-28.62% |
| 2020-12-31 | CN¥2.05 Billion ≈ $300.25 Million |
-14.80% |
| 2019-12-31 | CN¥2.41 Billion ≈ $352.41 Million |
+1.83% |
| 2018-12-31 | CN¥2.37 Billion ≈ $346.08 Million |
+4.24% |
| 2017-12-31 | CN¥2.27 Billion ≈ $332.01 Million |
-10.02% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.99 Million |
+111.16% |
| 2015-12-31 | CN¥1.19 Billion ≈ $174.75 Million |
+29.84% |
| 2014-12-31 | CN¥919.76 Million ≈ $134.59 Million |
+177.48% |
| 2013-12-31 | CN¥331.47 Million ≈ $48.50 Million |
-22.97% |
| 2012-12-31 | CN¥430.29 Million ≈ $62.96 Million |
+2.29% |
| 2011-12-31 | CN¥420.66 Million ≈ $61.56 Million |
+1.72% |
| 2010-12-31 | CN¥413.53 Million ≈ $60.51 Million |
-39.55% |
| 2009-12-31 | CN¥684.14 Million ≈ $100.11 Million |
+5.16% |
| 2008-12-31 | CN¥650.60 Million ≈ $95.20 Million |
+36.27% |
| 2007-12-31 | CN¥477.43 Million ≈ $69.86 Million |
-1.78% |
| 2006-12-31 | CN¥486.08 Million ≈ $71.13 Million |
-4.78% |
| 2005-12-31 | CN¥510.48 Million ≈ $74.70 Million |
-7.20% |
| 2004-12-31 | CN¥550.11 Million ≈ $80.50 Million |
-2.40% |
| 2003-12-31 | CN¥563.64 Million ≈ $82.48 Million |
+63.86% |
| 2002-12-31 | CN¥343.98 Million ≈ $50.34 Million |
+180.86% |
| 2001-12-31 | CN¥122.47 Million ≈ $17.92 Million |
-37.95% |
| 2000-12-31 | CN¥197.38 Million ≈ $28.88 Million |
-4.42% |
| 1999-12-31 | CN¥206.51 Million ≈ $30.22 Million |
+184.70% |
| 1998-12-31 | CN¥72.54 Million ≈ $10.61 Million |
+58.70% |
| 1997-12-31 | CN¥45.70 Million ≈ $6.69 Million |
-35.37% |
| 1996-12-31 | CN¥70.71 Million ≈ $10.35 Million |
+98.97% |
| 1995-12-31 | CN¥35.54 Million ≈ $5.20 Million |
-- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more